Bioactive fraction of
The invention relates to a bioactive fraction of Petiveria alliacea having an antitumour activity, and to the use of same for producing medicaments for treating cancer. The invention also relates to a pharmaceutical combination for treating, comprising the bioactive fraction of Petiveria alliacea and at least one immunostimulant that can produce the phenotypic and/or functional maturation of the dendritic cells. The invention further relates to sequential administration of the bioactive fraction of Petiveria alliacea or the composition containing same and immunostimulant agent.
1. A bioactive fraction of Petiveria alliacea obtained by bioguided procedures, standardized and analytically marked for treating cancer, comprising:
% weight respect
COMPOUND
total bioactive fraction
4-ethyl petiveral
0.01-5
Lignoceric acid
0.01-5
Dibenzyl disulfide
0.01-5
Dibenzyl tetrasulfide
0.01-5
Dibenzyl trisulfide
3.8-7
Leridal-7-demethyl
3.8-7
Leridal Chalcone
0.01-5
Leridol
0.01-5
Myricitrine
0.01-5
Petiveral
20.6-38.2
Pinitol
0.01-5
S-benzyl cysteine sulfoxide
0.01-5
Senfol
0.01-5
wherein the bioactive faction decreases clonogenic capacity in tumour cells.
2. A The bioactive fraction of Petiveria alliacea obtained by bioguided procedures, standardized and analytically marked for treating cancer according to claim 1 , wherein the bioactive fraction comprises the following chromatographic fingerprint in an analysis by HPLC coupled to UV detector at 280 nm using RP-18 column and mobile phase (A) H 2 O+formic acid 1% and (B) MeOH+formic acid 0.1% according to the elution gradient −60% solvent A since 0 until 5 minutes, 0% solvent A in 45 minutes and 60% solvent A since 52 until 62 minutes:
Peak
Retention time (min)
1
8.31
2
20.38
3
22.58
4
26.68
5
28.32
6
34.12.
3. A The bioactive fraction of Petiveria alliacea obtained by bioguided procedures, standardized and analytically marked for treating cancer according to claim 1 , wherein the bioactive fraction comprises the following chromatographic fingerprint in an analysis by HPLC coupled to PDA detector using RP-18 column and mobile phase H20: CAN (4:6):
Peak
Retention time (min)
λ (nm)
1
29.37
324
2
33.42
265
3
48.27
265.
4. A pharmaceutical composition for treating cancer comprising the bioactive fraction of Petiveria alliacea according to claim 1 and at least one or more pharmaceutically acceptable excipients.
5. A kit for treating cancer comprising the first pharmaceutical composition according to claim 4 , a second pharmaceutical composition containing one or more immunostimulant agents that can produce the phenotypic and/or functional maturation of the dendritic cells and at least one or more pharmaceutically acceptable excipients and optionally instructions for use.
6. A pharmaceutical combination for treating cancer comprising the bioactive fraction of Petiveria alliacea according to claim 1 and at least one immunostimulant agent that can produce the phenotypic and/or functional maturation of the dendritic cells.
7. The pharmaceutical combination for treating cancer according to claim 6 wherein the immunostimulant agent that can produce the phenotypic and/or functional maturation of the dendritic cells is a polysaccharide and/or glycopeptide obtained from: Ganoderma lucidum, Astragalus membranaceus, Grifola frondosa, Phellinus linteus, Cordyceps militaris, Lentinus edodes, Coriolus vericolor, Agaricus blazei or Petiveria alliacea.
8. A bioactive fraction of Petiveria alliacea obtained by bioguided procedures, standardized and analytically marked for treating cancer, comprising:
% weight respect
COMPOUND
total bioactive fraction
4-ethyl petiveral
0.01-5
Lignoceric acid
0.01-5
Dibenzyl disulfide
0.01-5
Dibenzyl tetrasulfide
5-9.5
Dibenzyl trisulfide
4.5-8.7
Leridal-7-demethyl
0.01-5
Leridal chalcone
19-36
Leridol
8-15
Myricitrine
0.01-5
Petiveral
32-55
Pinitol
0.01-5
S-benzyl cysteine sulfoxide
2-5
Senfol
0.01-5
wherein the bioactive fraction induces early nonreversible mitochondrial membrane depolarization and decreases Hsp70 expression on tumoural cells.
9. A pharmaceutical composition for treating cancer comprising the bioactive fraction of Petiveria alliacea according to claim 8 and at least one or more pharmaceutically acceptable excipients.